Alliance/CALGB 50303 was an intergroup, randomized phase III study, which aimed to compare the efficacy of R-CHOP to DA-EPOCH-R in patients with untreated DLBCL 25. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.